摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,7,3'-trihydroxyflavone

中文名称
——
中文别名
——
英文名称
6,7,3'-trihydroxyflavone
英文别名
6,7,3'-trihydroxflavone;6,7-dihydroxy-2-(3-hydroxyphenyl)chromen-4-one
6,7,3'-trihydroxyflavone化学式
CAS
——
化学式
C15H10O5
mdl
——
分子量
270.241
InChiKey
YLQLFNHURAYJDR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    87
  • 氢给体数:
    3
  • 氢受体数:
    5

ADMET

代谢
6,7,3p-三羟黄酮已知的人类代谢物包括(2S,3S,4S,5R)-3,4,5-三羟基-6-[6-羟基-2-(3-羟基基)-4-杂色-7-基]环己烷-2-羧酸
6,7,3p-Trihydroxflavone has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[6-hydroxy-2-(3-hydroxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylic acid.
来源:NORMAN Suspect List Exchange

反应信息

  • 作为反应物:
    描述:
    6,7,3'-trihydroxyflavoneUDP-glucuronic acid 在 human UDP-glucuronosyltransferase 1A9 、 magnesium chloride 、 alamethicin 、 糖质酸-1,4-内酯 作用下, 生成 (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[6-hydroxy-2-(3-hydroxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylic acid
    参考文献:
    名称:
    Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches
    摘要:
    通过实验使用145种酚类化合物,并通过3D-QSAR方法分析,确定了人UGT1A9的催化选择性。UGT1A9是一种重要的膜结合酶,催化外源性物质的葡糖醛酸化反应。通过动力学分析确定了UGT1A9的催化效率。使用CoMFA和CoMSIA技术分析了定量结构活性关系。通过将葡糖醛酸化位点及其相邻的芳香环重叠,实现了底物结构的最大立体重叠。对于具有多个活性葡糖醛酸化位点的底物,每个位点被视为单独的底物。3D-QSAR分析产生了统计上可靠的模型,具有良好的预测能力(CoMFA:q2=0.548,r2=0.949,r pred 2=0.775;CoMSIA:q2=0.579,r2=0.876,r pred 2=0.700)。通过轮廓系数图阐明了底物中负责选择性差异的结构特征。将轮廓系数图叠加在UGT1A9的同源模型的催化口袋中,能够高度自信地识别UGT1A9的催化口袋。CoMFA/CoMSIA模型可以预测底物的选择性和UGT1A9的体外清除率。我们的发现还提供了理解UGT1A9功能和底物选择性的可能分子基础。
    DOI:
    10.1007/s11095-012-0666-z
点击查看最新优质反应信息

文献信息

  • Anti-glycation agents for preventing age- diabetes- and smoking-related complications
    申请人:Yeboah Faustinus
    公开号:US20050043408A1
    公开(公告)日:2005-02-24
    The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.
    这项发明提供了新的蛋白质糖基化抑制剂,通过高通量筛选检测从化合物库中鉴定出来。所鉴定的抗糖基化剂具有多种化学结构,可用于预防或治疗与年龄、糖尿病和吸烟有关的并发症,包括神经病变、肾病、眼部病理或胶原组织的机械性能丧失。在被鉴定为具有抗糖基化活性的化合物中,特别感兴趣的是肾上腺素及其类似物,特别是D-肾上腺素及其类似物,可用于预防或治疗与年龄、糖尿病和吸烟有关的眼部病理。
  • ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS
    申请人:YEBOAH Faustinus
    公开号:US20080139664A1
    公开(公告)日:2008-06-12
    The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.
    该发明提供了新的蛋白质糖基化抑制剂,通过高通量筛选检测从化合物库中确定。所确定的抗糖基化剂具有各种化学结构,并可用于预防或治疗与年龄、糖尿病和吸烟相关的并发症,包括神经病变、肾病、眼部病理或胶原组织机械性能的丧失。在被确定为具有抗糖基化活性的化合物中,特别感兴趣的是肾上腺素及其类似物,特别是D-肾上腺素及其类似物,这些物质特别适用于预防或治疗与年龄、糖尿病和吸烟相关的眼部病理。
  • Compounds exhibiting efflux inhibitor activity and composition and uses thereof
    申请人:Wempe Fitzpatrick Michael
    公开号:US20070254859A1
    公开(公告)日:2007-11-01
    At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
  • [EN] ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS<br/>[FR] AGENTS ANTI-GLYCATION DESTINES A LA PREVENTION DES COMPLICATIONS LIEES A L'AGE, AU DIABETE ET AU TABAGISME
    申请人:CA NAT RESEARCH COUNCIL
    公开号:WO2003032969A2
    公开(公告)日:2003-04-24
    The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.
查看更多